1] Drug development for neuroprotection: in vitro and in vivo models

2] Synaptic plasticity, learning and memory

3] Anti-cancer drug development

4] Osteoporosis, bone formation and bone resorption

5] Gnen defect related to parkinsonism, schizophrenia

6] Neuropathic pain

Many degenerative central neuronal diseases (for example: stroke, parkinsonism, Huntington’s disease and Alzheimer’s disease) are not very satisfactorily managed. It is very important to develop neuroprotectants to prevent neuronal death induced by ischemia-reperfusion, free radical, dopamine, b-amyloid peptide etc. We focus on the develop of the neuroprotective agents for the following neurodegenerative diseases, such as stroke, Parkinsonism, Huntington’s disease, glutamate-induced neurotoxicity and Alzheimer’s disease with the specific animal models and the primary cultures. We have also found a few compounds which are able to enhance learning and memory. In addition, we also deveted to the study of neuronal plasticity, mechanism and treatment of neuropathic pain. To address this, electrophysiological, immunohistochemistry and biochemical approaches are used. We also corporate with clinician to study the metabolism of bone and develop new drugs for the treatment of osteoporosis and cancer metastasis to bone. Bone formation and bone resorption are evaluated using both in vitro cell cultures and in vivo animal models. We have technically transferred a protein drug targeting avb3 integrin to pharmaceutical company.

近期代表著作：

1] Leukemia Inhibitory Factor (LIF) Potentiates Antinociception Activity and Inhibits Tolerance Induction of Opioids. British Journal of Anaesthesia, 2016 (In Press).

2] Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice. PLoS One 2015; 23;10(2) [Abstract]   

3] Inhibition of hyperactivity and impulsivity by carbonic anhydrase inhibitors in spontaneously hypertensive rats, an animal model of ADHD. Psychopharmacology (Berl). 2015; 232: 3763-72. [Abstract]  

4] Novel pyrazole derivatives effectively inhibit osteoclastogenesis, a potential target for treating osteoporosis. J. Med. Chem. 2015; 58: 4954-63.

    [Abstract] 

5] LC3 overexpression reduces Aβ neurotoxicity through increasing α7nAchR expression and autophagic activity in neurons and mice. Neuropharmacology 2015; 93: 243-51.  [Abstract]  

6] Role of spinal CXCL1 (GROα) in opioid tolerance: a human-to-rodent translational study. Anesthesiology 2015;122: 666-76.  [Abstract] 

1] Neuroprotection: cortex neuronal culture, animal models using different compounds for the induction of different neurodegenerative diseases.

2] Behavioral models for the study of learning and memory: rotarod, water maze, passive and active avoidance.

3] Brain slice: for the study of neuronal plasticity, long-term potentiation.

4] Chung’s neuropathic model and formalin-induced pain: developing drugs for the treatment of pain.

5] Osteoblast and osteoclast cultures: for the study of bone metabolism and the development of drugs for the treatment of osteoporosis.

6] Induction of osteoporosis by sciatic nerve section or ovarictomy.

1] Set up for patch clamp recordings: including amplifiers, pClamp software, air table, manipulator, oscilloscope

2] Biometra RT-PCR instrument

3] Set up for brain slice recordings